Home › Amblyopia › Pennsylvania › Philadelphia
Amblyopia clinical trials in Philadelphia, PA
4 studies for Amblyopia are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
RecruitingPhase 3
- Wills Eye Hospital, Philadelphia
- Pennsylvania College of Optometry, Salus at Drexel University, Philadelphia
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
RecruitingPhase 3
- Wills Eye Hospital, Philadelphia
- Salus University/Pennsylvania College of Optometry, Philadelphia
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
RecruitingPhase 3
- Wills Eye Hospital, Philadelphia
- Salus University/Pennsylvania College of Optometry, Philadelphia
Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
RecruitingObservational study
- Children's Hospital Of Philadelphia, Philadelphia
About Amblyopia
Learn about amblyopia, or "lazy eye," the most common cause of visual problems in children. It happens when an eye fails to work properly with the brain.
More about Amblyopia on MedlinePlus
Amblyopia trials in other cities
- Boston, MA4 studies
- Columbus, OH4 studies
- Chicago, IL4 studies
- Naperville, IL4 studies
- Dallas, TX4 studies
- Fort Lauderdale, FL3 studies
- Cleveland, OH3 studies
- Durham, NC3 studies
- Berkeley, CA3 studies
- San Francisco, CA3 studies
- Memphis, TN3 studies
- Lancaster, PA3 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Prostate Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.